FTXH:NSD-First Trust Nasdaq Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 28.56

Change

-0.07 (-0.23)%

Market Cap

USD 0.02B

Volume

1.80K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and ranking. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
IBB iShares Biotechnology ETF

-0.56 (-0.39%)

USD 7.19B
PPH VanEck Pharmaceutical ETF

-0.05 (-0.06%)

USD 0.67B
BBH VanEck Biotech ETF

+0.36 (+0.21%)

USD 0.43B
PSCH Invesco S&P SmallCap Health Ca..

-0.51 (-1.07%)

USD 0.18B
PTH Invesco DWA Healthcare Momentu..

-0.29 (-0.62%)

USD 0.14B
GNOM Global X Genomics & Biotechnol..

+0.03 (+0.28%)

USD 0.08B
CNCR Loncar Cancer Immunotherapy ET..

-0.29 (-1.93%)

USD 0.01B

ETFs Containing FTXH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.31% 50% F 61% D-
Dividend Return 1.19% 80% B- 25% F
Total Return 8.50% 50% F 59% D-
Trailing 12 Months  
Capital Gain 16.29% 38% F 61% D-
Dividend Return 1.80% 83% B 27% F
Total Return 18.08% 38% F 59% D-
Trailing 5 Years  
Capital Gain 32.53% 75% C 66% D+
Dividend Return 7.27% 71% C- 22% F
Total Return 39.80% 75% C 64% D
Average Annual (5 Year Horizon)  
Capital Gain 4.97% 75% C 53% F
Dividend Return 6.10% 88% B+ 52% F
Total Return 1.13% 75% C 29% F
Risk Return Profile  
Volatility (Standard Deviation) 8.33% 100% F 90% A-
Risk Adjusted Return 73.21% 88% B+ 89% A-
Market Capitalization 0.02B 25% F 17% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.